Remove Biomarkers Remove Cancer Remove Outcomes
article thumbnail

Soluble immune-checkpoint factors: a potential immunotherapy biomarker

Journal of Clinical Investigation - Cardiology

There is unmet need for additional biomarkers to better select patients with non–small cell lung cancer (NSCLC) that are likely to benefit from immunotherapy in order to improve patient outcomes, reduce patient toxicity, and relieve the growing burden of healthcare costs.

article thumbnail

Unhealthy visceral fat is associated with improved efficacy of immunotherapy in endometrial cancer

Journal of Clinical Investigation - Cardiology

Obesity is a known driver of endometrial cancer. In this issue of the JCI, Gómez-Banoy and colleagues investigated a cohort of patients with advanced endometrial cancer treated with immune checkpoint inhibitors targeting the interaction between programmed cell death receptor-1 (PD-1) and its ligand (PD-L1).

Cancer 82
article thumbnail

Biomarkers in heart failure: a focus on natriuretic peptides

Heart BMJ

HF affects around a million people in the UK and has a worse prognosis than most cancers. A timely diagnosis and initiation of evidence-based treatments are key to prevent hospitalisation and improve outcomes in this population. Biomarkers have dramatically impacted the way patients with HF are evaluated and managed.

article thumbnail

Circulating biomarkers in the diagnosis and prognosis of immune checkpoint inhibitor-related myocarditis: time for a risk-based approach

Frontiers in Cardiovascular Medicine

Immune checkpoint inhibitors (ICIs) are monoclonal antibodies that block immune checkpoints and therefore activate immune cells, allowing them to recognize and attack cancer cells. ICIs have revolutionized oncology practice, but their use has been complicated by immune-related adverse events (irAEs).

article thumbnail

Von Willebrand Factor Antigen Levels Predict Poor Outcomes in Patients With Stroke and Cancer: Findings From the Multicenter, Prospective, Observational SCAN Study

Journal of the American Heart Association

BackgroundPatients with acute ischemic stroke and active cancer have more severe neurological symptoms, elevated risks of stroke recurrence, and death compared with the general population. 30.78];P<0.05).ConclusionsElevated

Cancer 40
article thumbnail

Sublobar Resection Versus Lobectomy for Early-Stage Lung Cancer: A Debate

Society of Thoracic Surgeons - Surgeon

While both trials showed similar results, there are important differences in design, demographics, and patients’ outcomes. Plan to attend Part 2 on Thursday, December 14, titled " Biomarker Testing and Neoadjuvant Immunotherapy for Resectable NSCLC."

Cancer 52
article thumbnail

ACE Inhibitor Not Protective Against Heart Damage from Chemotherapy

DAIC

The PROACT study reported no impact on cardiotoxicity biomarkers or secondary endpoints related to heart function among patients who took high doses of enalapril, an ACE inhibitor, along with high doses of anthracyclines. Anthracyclines are a well-established class of cancer drugs that are used to treat several types of cancer.